SEATTLE, Wash. — June 9, 2021 — Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced successful results from an independent pre-clinical study validating the company’s Bio-RFID™ platform technology. Know Labs is developing a novel medical device using the Bio-RFID technology that it expects will…

Sign Up for Updates at particlebulb.com Seattle, WA. — March 24, 2021 — OTCQB: KNWN Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, through its proprietary electromagnetic energy technology platforms, today shares with the public preliminary study results from Texas Biomedical Research Institute (Texas Biomed) indicating the Particle…

$14.2 Million for Product Development, Clinical Testing and Preparation for Up List to a Major Exchange Seattle, WA. — March 15, 2021 — OTCQB: KNWN Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, through its proprietary electromagnetic energy technology platforms, announced today that it has closed on $14.2…

Announces Company Highlights and Developments at its Subsidiary, Particle, Inc. Seattle, WA. — February 09, 2021 — OTCQB: KNWN Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, through its patented and patent pending electromagnetic energy technology platforms, announced today that it intends to list on a major national…

Seattle, WA. — December 3, 2020 — OTCQB: KNWN Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, announced that its efforts to test and validate its patented Bio-RFID™ platform technology for non-invasive glucose monitoring with third-party research organizations have been temporarily slowed by the impact of Covid-19. Phil…

Seattle, WA. — July 21, 2020 — OTCQB: KNWN Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, announced today that it has entered into a Research Agreement with Mayo Clinic to test and validate its patented Bio-RFID™ platform technology. Know Labs plans to first deploy its Bio-RFID platform in its wearable UBAND™ as a non-invasive Continuous Glucose Monitor (CGM). Phil Bosua, Know Labs CEO, stated, “We are very pleased to work with Mayo Clinic. They bring a world-renowned reputation in diagnostics. We look forward to working with them during this research project as we continue the development of our non-invasive UBAND CGM.”

Seattle, WA — April 13, 2020 — OTCQB: KNWN Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, announced the publication of a webcast hosted by BioPub, a biotech investment and discussion website found at www.biopub.co. The webcast can be found at this link. The webcast was moderated by BioPub’s founder and editor in chief, Dr. KSS, MD, Ph.D. Participants from Know Labs included CEO, Phil Bosua, and Chairman, Ron Erickson.

Invention to Disrupt Medical Diagnostics Patent Protected Seattle, WA. — April 7, 2020 — OTCQB: KNWN Know Labs, Inc. an emerging leader in non-invasive medical diagnostics, today announced that it has been granted a patent on its Bio-RFID technology. …

CEO Discusses IP, Improvements to Algorithm, and Website Redesign Seattle, WA. — February 5, 2020 — OTCQB: KNWN Know Labs, Inc. today released a video updating viewers on their latest progress. The link to the video can be found here. In the video, Know Labs CEO, Phil Bosua, announces the redesign of the Company’s website and discusses the continuing patent work. He also provides updates on selecting materials to be used in the UBAND and advances made on the Company’s algorithm.